Celldex Therapeutics, Inc.
CLDX
$18.30
$0.502.81%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -63.18% | 27.74% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -63.18% | 27.74% | |||
| Cost of Revenue | 3.70% | 1,065.37% | |||
| Gross Profit | -8.78% | -2,935.50% | |||
| SG&A Expenses | 2.08% | 10.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.41% | 13.32% | |||
| Operating Income | -7.48% | -12.54% | |||
| Income Before Tax | -11.80% | -17.52% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.80% | -17.52% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.80% | -17.52% | |||
| EBIT | -7.48% | -12.54% | |||
| EBITDA | -7.53% | -12.79% | |||
| EPS Basic | -11.69% | -17.04% | |||
| Normalized Basic EPS | -11.71% | -17.04% | |||
| EPS Diluted | -11.69% | -17.04% | |||
| Normalized Diluted EPS | -11.71% | -17.04% | |||
| Average Basic Shares Outstanding | 0.09% | 0.42% | |||
| Average Diluted Shares Outstanding | 0.09% | 0.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||